TrialBlood advances2022

Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.

Hema Dave et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.